

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Vivian Tang, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594-6208, tangvw@csr.nih.gov.

Name of Committee: Healthcare Delivery and Methodologies Integrated Review Group; Organization and Delivery of Health Services Study Section.

Date: October 22-23, 2026.

Time: 9:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Mary Kate Baker, DRPH, MPH, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301-594-5117, katie.baker2@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: September 11, 2026.

Rosalind M. Niamke,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026-18953 Filed 9-15-26; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the invention listed below, which is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT:

Inquiries related to this licensing opportunity should be directed to: Dawn Taylor-Mulneix, or dawn.taylor-mulneix@nih.gov. Licensing information

may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

SUPPLEMENTARY INFORMATION:

Technology description follows:

Respiratory Syncytial Virus (RSV) G and F Specific Antibodies With High RSV-Neutralizing Potency

Description of Technology

RSV is a major cause of serious respiratory illness, particularly in infants, older adults, and people with weakened immune systems. The virus uses the attachment protein G to bind to host cells and the fusion protein F to enter them. Although approved RSV antibody products target F, no licensed antibody currently targets G.

Researchers in NIAID's Laboratory of Infectious Diseases (LID) developed a monoclonal antibody that targets a conserved region of G that may be less likely to change over time. In laboratory tests, the IgG3 subclass of this antibody showed about 9-fold greater neutralizing activity than licensed RSV antibodies. Researchers also created an IgG1 version to see whether the IgG3 subclass contributed to this strong activity. The IgG1 version was slightly less potent than the IgG3 form but still showed strong neutralizing activity. These results suggest that IgG subclass can influence the neutralizing activity of this G-targeting antibody.

This technology could support development of first-in-class antibodies targeting RSV G for the prevention or treatment of RSV disease, including in people at high risk for severe illness. These G-targeting antibodies may also be used in combination with existing F-targeting antibodies to broaden protection and potentially improve efficacy. Ongoing engineering efforts are aimed at improving the stability of the G-targeting antibodies and extending their persistence in the body.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

Potential Commercial Applications

- Antibody-based RSV products targeting the attachment protein G that may be used alone or in combination

with existing RSV F-targeting antibodies to broaden protection.

- Potential first-in-class antibodies against the RSV G protein for preventing or treating severe disease.

Competitive Advantages

- Target the RSV attachment protein G, for which no licensed antibodies currently exist.
- Bind a conserved region of the G protein that may be less likely to change over time, which could help these antibodies remain effective as the virus evolves.
- IgG3 G-targeting antibody achieves about 9-fold greater neutralizing activity in laboratory tests than currently existing products.

Development Stage

- Pre-Clinical

Inventors: Dr. Ursula Buchholz, Dr. Cyril Le Nouen, and Dr. Laura Ahlers, all of NIAID.

Intellectual Property: HHS Reference No. E-117-2024-0. Provisional Patent Application No. 63/566,064, filed on March 15, 2024, and PCT Patent Application No. PCT/US2025/020070, filed on March 14, 2025.

Licensing Contact: To license this technology, please contact Dawn Taylor-Mulneix at 301-451-8021, or dawn.taylor-mulneix@nih.gov, and reference E-117-2024-0.

Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Dawn Taylor-Mulneix at 301-451-8021, or dawn.taylor-mulneix@nih.gov.

Dated: September 11, 2026.

Surekha Vathyam,

Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2026-18954 Filed 9-15-26; 8:45 am]

BILLING CODE 4167-05-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Applied Immunology and Disease Control Integrated Review Group; Vaccines Against Infectious Diseases Study Section, October 15,